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Abstract
Background: Rates of surgical site infections (SSIs) following groin incision for femoral artery exposure are much
higher than expected of a clean operation. The morbidity and mortality is high, particularly with the use of prosthetic
grafts. The vascular surgery population is at an increased risk of SSIs related to peripheral vascular disease (PVD),
diabetes, obesity, previous surgery and presence of tissue loss. Negative pressure wound therapy (NPWT) dressings
have been used on primarily closed incisions to reduce surgical site infections in other surgical disciplines. We have
not come across any randomized controlled trials to support the prophylactic use of negative pressure wound therapy
in high-risk vascular patients undergoing lower limb revascularization.
Methods/design: In this single-center, prospective randomized controlled trial, patients scheduled for a lower limb
revascularization requiring open femoral artery exposure who are at a high risk (BMI > 30 kg/m2, previous femoral
cutdown or Rutherford V or VI category for chronic limb ischemia) will be eligible for the study. A total of 108 groin
incisions will be randomized to the use of a negative pressure wound device or standard adhesive gauze dressing.
Patients will be followed in hospital and reassessed within the first 30 days postoperatively. The primary outcome is SSI
within the first 30 days of surgery and will be determined using the intention-to-treat principle. Secondary outcomes
include length of stay, emergency room visits, reoperation, amputation and mortality. A cost analysis will be performed.
Discussion: The trial is expected to define the role of NPWT in SSI prophylaxis for lower limb revascularization in
high-risk vascular patients. The results of the study will be used to inform current best practice for perioperative
care and the minimization of SSIs.
Trial registration: NCT02084017, March 2014
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Background
Surgical site infections (SSIs) at the groin incision fol-
lowing lower extremity revascularization procedures
have been reported as up to 30 % [1–6]. This is signifi-
cantly higher than expected in a surgical wound classi-
fied as clean, 2.1–3.3 % [7]. A number of risk factors
within this population has been identified as risk factors
for SSIs and include obesity, previous femoral cutdown
and presence of critical limb ischemia [8, 9]. Significant
morbidity associated with SSIs in lower extremity revascu-
larization includes increased length of stay, sepsis, hospital
readmissions, limb loss, and death [10, 11]. Further, the
cost of vascular SSIs has been recently estimated to add
US$10,000 to the cost of care per patient [11].
A variety of methods including topical antibiotics,
antibiotic-impregnated grafts, and platelet-rich plasma
have all been used with limited success [12]. Negative
pressure wound therapy (NPWT) is a relatively new
treatment modality that has also demonstrated some evi-
dence in SSI prevention in incisions closed primarily,
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including groin incisions [6, 13, 14]. However, there are
currently no randomized controlled trials investigating
the use of NPWT to prevent SSIs following lower limb
revascularization.
The objective of this study is to assess the role of
NPWT, using the Prevena Incision Management System
(Kinetic Concepts Inc, San Antonio, TX, USA), in pri-
mary closed groin incisions in patients requiring femoral
artery exposure for lower limb revascularization on de-
creasing SSI compared to standard sterile gauze dress-
ing. We hypothesize that patients randomized to NPWT
will have a lower incidence of SSI in the groin incision
within the first 30 days of surgery compared to patients
randomized to the control group.
Methods/design
Western University ethics board performed a full-board
review and approved the trial (REB 104871). The trial is
registered at Clinicaltrials.gov (NCT02084017). The
study will be funded by the Department of Surgery Resi-
dent Research grant from Western University. Kinetic
Concepts Inc. (San Antonio, TX, USA) will donate all
NPWT devices for this trial and will not have any influ-
ence in study design, data collection, statistical analysis
or writing of the final manuscript.
Study design
This will be a single institution, prospective, randomized,
open-label trial, in which eligible patients will be ran-
domized to NPWT or a standard dressing of groin inci-
sion using a block randomization.
Study setting
The study will take place at the Victoria Hospital of
London Health Sciences Center (LHSC) in London, ON,
Canada: Victoria Hospital is an academic teaching
hospital and is associated with the Schulich School of
Medicine and Dentistry at Western University.
Eligibility
High-risk patients scheduled for a lower limb revascular-
ization requiring groin incision for a femoral artery ex-
posure are eligible for the study. Example operations
include but are not limited to femoral to femoral artery
crossover bypass, femoral to distal artery bypass, and
femoral artery endarterectomy. Before the enrolment,
informed consent will be obtained from each patient.
Primary author KL will identify and be responsible for
enrolling all the eligible patients.
Inclusion criteria
Patients must be 18 years or older and scheduled for a
lower limb revascularization operation requiring femoral
artery exposure. Groin incision must be closed primarily
in the operating room. Patients with one of the high-risk
factors: obesity (body mass index > 30 kg/m2), previous
femoral artery exposure or presence of minor or major
tissue loss, will be included in the study.
Exclusion criteria
Patients who have a pre-existing groin infection, a
known sensitivity/allergy to adhesive material or on
whom a complete seal of NPWT cannot be obtained at
the time of device application will be excluded.
Intervention and control
The intervention group will have NPWT, the Prevena
Incision Management System (Kinetic Concepts Inc, San
Antonio, TX, USA), applied to the primary closed groin
incision. The Prevena system has a silver interface with
a foam layer connected to a small portable battery-
operated vacuum unit. The vacuum is preset to continu-
ous at 125 mmHg. The device is applied under sterile
conditions in the operating room and remains on the
patient until the hospital discharge or postoperative day
8, whichever occurs first. The wound will be inspected
for any evidence of infection once the Prevena is re-
moved. The device is used only once and is disposed of
at the end of the study. Any concern about the wound
or the device will require removal of the NPWT earlier
than planned and will be recorded as a secondary end-
point of the trial.
The control group will have a standard sterile gauge
dressing to cover the groin incision. The postoperative
management is typically removal of the dressing on day
2 postoperatively with daily dressing changes thereafter.
All other pre- and postoperative care of patients will be
the same in both groups. Hair will be removed with elec-
tric clippers preoperatively. Skin preparation will be
done with 2 % chlorhexidiene. Every patient will received
preoperative antibiotics (cephalexin or vancomycin if
penicillin allergy is present) and postoperative antibiotics
will be given for 48 h. At the end of the operation, the
groin incision will be primary closed with either skin
staples, monocryl or prolene sutures.
Randomization, allocation concealment and blinding
Once the groin incision is primary closed, randomization
will be done using internet-based software, sealedenvelo-
pe.com (London, UK), via random permutated blocks. If
the patient has bilateral groin incisions, the right groin
will be randomized and the left groin will be automatic-
ally placed in the other arm. The surgical team, clinical
staff, and patient will not be blinded to the intervention
status. The primary outcome of SSI will be assessed by a
clinical specialist nurse who will be blinded to the inter-
vention status.
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Definition of primary endpoint and outcome measures
The primary endpoint is the incidence of superficial SSI
within 30 days of surgery. SSI is defined by the Center
for Disease Control and Prevention (CDC) criteria [15]
as: infection occurring within the first 30 postoperative
days involving skin and subcutaneous tissue of the
incision and at least one of the following:
1. Purulent drainage from the incision
2. Organisms isolated from an aseptically obtained
culture of fluid or tissue from the incision
3. At least one of the following signs/symptoms of
infection




OR incision is deliberately opened by a surgeon
(unless incision is culture negative)
4. Diagnosis of SSI by the surgeon or attending
physician
Once the SSI is identified, the Szilagyi classification of
vascular wound infections will be used to classify to in-
fection [16]. This classification categorizes vascular SSI
based on dermal involvement (I), subcutaneous involve-
ment (II) or arterial graft involvement (III).
SSI will be assessed daily, at discharge, and reassessed
at the outpatient clinic within 30 days following the
operation.
Secondary endpoints
Secondary endpoints include length of stay, emergency
room visits, SSI requiring surgical intervention, deep SSI
occurring within 90 days of an operation, limb amputa-
tion, and mortality. A cost analysis will also be per-
formed using the average cost provided by LHSC for
inpatients, return visits, and any surgical intervention.
Outcomes related to potential harm will also be identi-
fied including local reaction to the NPWT device, and
the need for early removal of the dressing.
Sample size
Our previous study revealed a SSI rate of 22 % in all pa-
tients requiring femoral artery exposure for vascular sur-
gical procedure at LHSC [4]. This study will only
include high-risk patients as defined above and we ex-
pect the wound infection rate to be higher. Matatov et
al. demonstrated a reduction of groin SSI with NPWT
from 30 % to 6 %, an absolute risk reduction of 24 %
and relative risk reduction of 80 % [6]. Given an alpha of
0.05, for 80 % power, this yields a required sample size
of 48 patients per group using the Fleiss method with
continuity correction. The planned sample size will ac-
count for potential loss of follow-up, device malfunction
and patient incompliance and has been adjusted to a
final sample size of 54 (10 % increase from calculated
sample size) groin incisions per group and a total study
sample of 108 groin incisions. The timeline for recruit-
ment is 20 months and with a 90-day follow-up the
study will be concluded in 2 years.
Data collection and management
All data collected will be recorded on paper forms and
will be kept within the patient charts. Data will be col-
lected by the surgical team and trial personnel. Accuracy
of data collection will be ensured by the study personnel
not involved with data management or analysis by per-
forming sample assessments at regular intervals. Any ad-
verse events due to NPWT that causes morbidity or
mortality will be recorded and reported to the primary in-
vestigator and institutional ethics committee. We expect
minimal to no harm from the use of NPWT in this trial
based on a previous report using the same device [6].
Statistical analysis
All analysis will be prespecified and conducted according
to the intention-to-treat principle with the use of SPSS
version 20 (IBM, Armonk, NY, USA). Each incision will
be randomized to the NPWT or standard dressing
group. In the case that a patient requires bilateral inci-
sions, the right side will be randomized and the left side
will be automatically placed in the opposite arm but not
be included in the primary analysis as there is a loss of
independence. Baseline characteristics of the two groups
will be recorded. The continuous variables will be com-
pared using Student’s t test. The categorical variables
will be compared using Pearson’s chi-square or Fisher’s
exact test depending on the number of events. The pro-
portion of SSIs amongst randomized groins will be com-
pared between the NPWT and standard dressing groups
using a chi-square test or Fisher’s exact tests depending
on the number of events. An absolute risk increase/re-
duction for SSI will be presented for the use of NPWT,
as well as the number needed to treat to prevent a single
SSI. Patients lost to follow-up have the outcome last
assessed treated as his or her final outcome. A secondary
analysis will be performed including the nonrandomized
groin in patients with bilateral incisions. We will also
perform a subgroup analysis on just patients undergoing
bilateral incision using McNemar’s test.
Secondary outcomes will be compared between groups
using a chi-square test for categorical variables. Non-
normally distributed continuous variables will be com-
pared using the Mann–Whitney U test. A p value of less
than 0.05 will be considered significant and all tests will
be two-sided.
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Discussion
This trial is the first randomized controlled trial to in-
vestigate the role of NPWT in reducing the incidence of
SSIs following surgery for lower limb revascularization
in high-risk patients. Matatov et al. retrospectively
reviewed 115 groin incisions in 90 patients who received
either NPWT or adhesive gauze dressing following vas-
cular procedure [6]. The authors demonstrated a reduc-
tion of SSI from 30 % to 6 % and no grade II or III
infections in the NPWT cohort [6]. Our hypothesis is
that high-risk patients in this study will see a similar
benefit of reduction of SSIs.
Draining fluid following lower limb revascularization
is not a new concept and in the past surgical drains
placed deep in the wound have been investigated with
randomized trials and meta-analyses, which did not
show a reduced rate of SSI [17–19]. Significant research
has been invested into the mechanism of action of
NPWT on wound healing leading to four primary ef-
fects: macrodeformation; stabilization of the wound en-
vironment; reduced edema and microdeformation [17].
In conjunction with reticulated open-cell foam, such as
used in the current study, NPWT can have a stimulatory
effect on cellular proliferation and angiogenesis. Further,
by actively removing excessive interstitial fluid and
edema, it is thought secondary necrosis is reduced [18].
On a molecular level, cytokine and growth factor expres-
sion are modulated to an anti-inflammatory profile and
culminate in angiogenesis, remodeling and granulation
tissue [19]. The closed suction environment placed
under sterile conditions also effectively separates the in-
cision from the surrounding environment theoretically
preventing the inoculation of environmental bacteria.
This trial will clarify the role of NPWT and its poten-
tial for reduction in SSI in groin incisions for lower limb
revascularization. The major limitation of this trial is the
inability to blind the surgical team and the patient. We
will randomize the incisions once the incision is primary
closed to reduce the bias that could occur from the sur-
gical team.
The results of this trial will be used to determine the
role of NPWT in the prevention of SSI. If this interven-
tion is shown to be effective for the prevention of SSI in
this high-risk population, significant benefit with respect
to both patient morbidity and resource utilization may
be achieved.
Trial status
Enrollment started on August 13, 2014. Currently, 46
patients have been enrolled.
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